The term “Managed Access Program” refers to the authorized programs which allow patients access to hard-to-access medicines which are not available in their native country. At times patients cannot wait for investigational drugs to reach the market in such conditions such programs become savior. The other terms for Managed Access Program are “Compassionate Use”, “Expanded Access”, “Named Patient Supply”, “Special Access Schemes/Programs”, “Autorisations temporaires d’utilisation (ATU)” and others. We work on individual patients, on a Managed Access Program basis, in accordance with their treating healthcare professional. We favor them in accessing life-saving medicines when certain needs are fulfilled:
Managed access program helps patients and physicians access much-required medicines when other alternative options are exhausted, or the particular is not available in a specific country. Managed Access Program is also known as an Expanded Access Program (EAP), Early Access Program, Compassionate Use Program, and Named Patient Program (NPP). These programs help especially needy patients improve their quality of life or save patients’ lives. Such programs also facilitate accessing unlicensed medication from another country when patients have no alternative at the local level.
In almost every country in the World, any patient with a chronic disease, life-threatening, has the right to buy, import, or access medication that can improve or save their life. Every country has its own rules and regulations set up for importing such medicines. Ikris Pharma International (IPI) is the fastest-growing pharmaceutical consultancy and service organization globally, facilitating access to advanced medicines for needy patients in India or any part of the World via the Named Patient Program. They have already successfully assisted more than 600 patients through this program across different geographies in the World.
The other terms for "Managed Access Program" are: "Compassionate Use," "Expanded Access," "Named Patient Supply," "Special Access Schemes/Programs," "Autorisations temporary d'utilisation (ATU)," and others. Such programs help needy patients to access hard-to-access medicines in their native place, which are not authorized at that particular place yet. Making such medicines available to eligible patients allows companies to do the right thing and handle unsolicited patient drug requests in an ethical and regulated manner.
"Named-patient basis" is another way of obtaining medicine before authorization. A doctor requests a supply of an unauthorized medicine directly from the manufacturer to treat an individual patient under the doctor's direct responsibility. In all situations, the request must be unsolicited, and the following conditions must be fulfilled: